1. RLIP76 Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients
- Author
-
Ugur Bilge, S Akdeniz, Ö Duman, Berrin Aktekin, Nihal Olgaç Dündar, Guven Luleci, Deniz Ozel, Senay Haspolat, and Esra Manguoğlu
- Subjects
Drug ,rlip76 gene ,business.industry ,media_common.quotation_subject ,Drug resistance ,QH426-470 ,Pharmacology ,medicine.disease ,neuropharmacology ,polymorphism ,Denaturing high performance liquid chromatography ,Epilepsy ,Polymorphism (computer science) ,Genetics ,medicine ,epilepsy ,Original Article ,business ,Gene ,Allele frequency ,Genetics (clinical) ,Pharmacogenetics ,pharmacogenetics ,media_common - Abstract
RLIP76Gene Variants are not Associated with Drug Response in Turkish Epilepsy PatientsApproximately 30% of epileptic patients remain untreated, in spite of trials with maximum tolerable doses of more than one drug. The RalA binding protein 1 (RALBP1/RLIP76), a multifunctional, anti-apoptotic, multidrug transporter protein, has been proposed as being responsible for the drug resistance mechanism in epilepsy. We have investigated polymorphic differences in the coding regions and exon-intron boundaries of theRLIP76gene, between 146 refractory and 155 non refractory epileptic patients in Turkey, using denaturing high performance liquid chromatography (HPLC) and sequencing analysis techniques. We have detected the following sequence variants: c.160-4G>A, c.187C>G, c.1562-38G>A, c.1670+107G>A, c.1670+93G>A, c.1670+96G>A, c.1670+100C>T, c.1670+130C>T, c.1670+131G>C, c.1670+140 G>C, and found no statistically significant correlation between allele frequencies and drug response status. We conclude that sequence variants of this gene are not involved in drug resistance in epilepsy.
- Published
- 2011